8-K: Current report filing
Published on November 17, 1998
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) November 17, 1998
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Charter)
Virginia
(State or Other 56-1641133
Jurisdiction of 001-13467 (IRS Employer
Incorporation) (Commission File Number) Identification No.)
911 East Leigh Street, Suite G-19,Richmond, Virginia 23219
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (804) 648-3820
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
99.1 Press Release, dated November 17, 1998, relating to
the receipt by the Registrant of a report relating to
HepArrest, the Registrant's lead human pharmaceutical.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC.
By: /s/ Robert B. Harris, Ph.D.
---------------------------
Robert B. Harris, Ph.D.
President
November 17, 1998
EXHIBIT INDEX
Number Description of Exhibit
99.1 Press Release, dated November 17, 1998, relating
to the receipt by the Registrant of a report relating to
HepArrest, the Registrant's lead human pharmaceutical.